AJTMH Transactions of the Royal Society of Tropical Medicine and Hygiene
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 65(2), 2001, pp. 87-89
Copyright © 2001 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lessa, H.
Right arrow Articles by Carvalho, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lessa, H.
Right arrow Articles by Carvalho, E.
Related Collections
Right arrow Travel Medicine
Right arrow Health Outcomes
Right arrow Leishmaniasis
American Journal of Tropical Medicine and Hygiene, Vol 65, Issue 2, 87-89
Copyright © 2001 by American Society of Tropical Medicine and Hygiene

Research Articles


Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony

HA Lessa, P Machado, F Lima, AA Cruz, O Bacellar, J Guerreiro, and EM Carvalho

Mucosal leishmaniasis is characterized by an intense inflammatory reaction and tissue damage with few parasites in the lesion. On the basis of previous observations that suggest a possible role of tumor necrosis factor alpha (TNF-alpha) in the pathology of this disease, an open-label study was performed to evaluate the efficacy of the treatment with an inhibitor of TNF-alpha (pentoxifylline) associated to antimony therapy in 10 patients with refractory mucosal leishmaniasis. Patients were treated with pentavalent antimony (20 mg per kilogram of body weight per day) plus orally administered pentoxifylline 400 mg 3 times daily for 30 days. Nine of 10 patients fulfilled the criteria for cure: they experienced complete reepithelization of the mucosal tissue 90 days after therapy and displayed no evidence of relapse at 1 year of follow-up. The TNF-alpha levels before therapy (776 +/- 342 pg/mL) fell to 94 +/- 57 pg/mL (P < 0.05) within 60 days after therapy. Our results indicate that pentoxifylline plus antimony therapy should be considered in all patients with mucosal leishmaniasis that is refractory to treatment.


This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
G. Soares, A. Barral, J. M. Costa, M. Barral-Netto, and J. Van Weyenbergh
CD16+ monocytes in human cutaneous leishmaniasis: increased ex vivo levels and correlation with clinical data
J. Leukoc. Biol., January 1, 2006; 79(1): 36 - 39.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
D. R. Faria, K. J. Gollob, J. Barbosa Jr, A. Schriefer, P. R. L. Machado, H. Lessa, L. P. Carvalho, M. A. Romano-Silva, A. R. de Jesus, E. M. Carvalho, et al.
Decreased In Situ Expression of Interleukin-10 Receptor Is Correlated with the Exacerbated Inflammatory and Cytotoxic Responses Observed in Mucosal Leishmaniasis
Infect. Immun., December 1, 2005; 73(12): 7853 - 7859.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
V. S. AMATO, H. F. ANDRADE JR., V. A. NETO, and M. I. S. DUARTE
SHORT REPORT: PERSISTENCE OF TUMOR NECROSIS FACTOR-{alpha} IN SITU AFTER LESION HEALING IN MUCOSAL LEISHMANIASIS
Am J Trop Med Hyg, May 1, 2003; 68(5): 527 - 528.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
O. Bacellar, H. Lessa, A. Schriefer, P. Machado, A. Ribeiro de Jesus, W. O. Dutra, K. J. Gollob, and E. M. Carvalho
Up-Regulation of Th1-Type Responses in Mucosal Leishmaniasis Patients
Infect. Immun., December 1, 2002; 70(12): 6734 - 6740.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Society of Tropical Medicine and Hygiene.